Conflicts of Interest No conflict of interest.
Detection and clinical relevance of donor specific HLA antibodies: a matter of debate
Article first published online: 15 MAY 2012
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation
Special Issue: Special Focus - Antibody-Mediated Rejection
Volume 25, Issue 6, pages 604–610, June 2012
How to Cite
Roelen, D. L., Doxiadis, I. I. N. and Claas, F. H. J. (2012), Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. Transplant International, 25: 604–610. doi: 10.1111/j.1432-2277.2012.01491.x
- Issue published online: 15 MAY 2012
- Article first published online: 15 MAY 2012
- Received: 27 October 2011 Revision requested: 4 December 2012 Accepted: 10 April 2012
- histocompatibility and immunogenetics;
The introduction of new sensitive assays for the detection of HLA antibodies on basis of their binding to isolated HLA molecules has got an enormous impact on the decision-making process with respect to donor selection for sensitized patients. In the past, when only complement-dependent cytotoxicity was used as a tool to define HLA alloantibodies, the presence of donor specific antibodies (DSA) before transplantation was considered a contraindication for renal transplantation with that donor. The interpretation of the current DSA results is far more difficult and leads to a lot of discussions and controversy. The problems associated with the use of solid phase assays for clinical decision making and possible solutions are discussed.